The immune-tumor interface is known to be regulated by at least a dozen other sets of protein switches, which can modulate PD-1/PD-L1/PD-L2 mediated signaling and provide independent regulatory signals (2). The gene discussed is PDCD1LG2; the disease is neoplasm.